Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
University of Nottingham · Frimley Park Hospital · +39 more institutions
Abstract
U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p
Citation impact
- FWCI
- 29.73
- Percentile
- 100%
- References
- 37
Authors
55- DSDominick ShawCorresponding
University of Nottingham
- ARAna R. Sousa
Frimley Park Hospital
- SJStephen J. Fowler
University of Manchester
- LFLouise Fleming
Imperial College London
- GRGraham Roberts
NIHR Southampton Respiratory Biomedical Research Unit, St Mary's Hospital, David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, University of Southampton
Topics & keywords
- Medicine
- Asthma
- Internal medicine
- Cohort
- Comorbidity
- Eosinophil
- Depression (economics)
- Quality of life (healthcare)
Funding
- AAmgen
- AAstraZeneca
- EFEuropean Federation of Pharmaceutical Industries and AssociationsAwards: 115010, FP7/2007-2013
- NINational Institute for Health and Care ResearchAward: FP7/2007-2013
- UOUniversity of Southampton
- ICImperial College London
- ECEuropean CommissionAwards: 115010, FP7/2007-2013, 115446, 2007-2013, FP7/2007
- UVUniversiteit van Amsterdam
- SESemmelweis Egyetem
- GHGentofte Hospital
- KIKarolinska Institutet
- UDUniversità di Catania
- UUUmeå Universitet
- UDUniversité de Lyon